Last updated: June 16, 2026
Ravgen, Inc. v. Illumina, Inc. (1:20-cv-01644): Litigation Summary, Claims at Issue, and Patent/Portfolio Impact
Executive summary: Ravgen v. Illumina (S.D.N.Y., 1:20-cv-01644) is a patent-infringement dispute in which Ravgen accused Illumina of infringing asserted patents tied to sequencing-based methods and/or associated genomics workflows. The case posture is the key driver of risk for Illumina’s deployed sequencing platforms and for Ravgen’s valuation and licensing leverage. The litigation history, including any claim construction, dispositive rulings, and settlement or status outcomes, determines which asserted claim sets survive and whether Ravgen preserves enforceable leverage through remaining claims or appeal.
What patents does Ravgen assert in Ravgen v. Illumina (1:20-cv-01644)?
A complete, accurate litigation summary requires the asserted patent identifiers (numbers) and which claims were asserted. Without those specifics, an infringement-focused analysis cannot be completed to the precision required for business, licensing, or litigation decisions.
Which claim sets and theories are typically at issue in sequencing patent cases?
In disputes involving sequencing technologies, infringement theories often track one or more of these buckets:
- Sequencing-by-synthesis or related chemistry steps tied to specific analytical workflows.
- Sample preparation, target enrichment, or library construction workflows.
- Data processing, variant calling, genotyping, or downstream interpretation tied to specific compute steps.
- Method-of-use claims tied to specific clinical or research workflows.
Which defendants and products are usually implicated
Illumina-facing cases frequently target one or more of:
- Sequencer instruments (platform hardware).
- Consumables (reagents, flow cells, kits).
- Software pipelines (alignment/variant calling workflows).
- Managed services or cloud-based analysis.
What is the procedural history of 1:20-cv-01644 and what rulings matter?
A litigation summary must anchor on docket events: complaint filing, answer, claim construction timeline, any motion-to-dismiss or transfer activity, summary-judgment decisions, and trial or settlement status.
Key docket milestones that determine infringement and leverage
Business-relevant milestones include:
- Claim construction (Markman) rulings narrowing claim scope.
- Discovery disputes affecting timetables or admissibility.
- Summary judgment eliminating some or all asserted claims.
- Daubert rulings excluding expert testimony.
- Consent judgments, stays, or settlement agreements.
Why claim construction drives valuation
In sequencing and bioinformatics, claim terms often map to:
- “comprising” step ordering and required sequencing of sub-steps.
- specific parameter thresholds and thresholds for quality control.
- required computational steps (for example, calling, filtering, phasing) rather than generic analysis.
What infringement claims and defenses typically govern Illumina-facing patent suits?
Without the complaint’s specific asserted claims and the docket’s rulings, it is not possible to give a case-correct analysis of the defenses actually litigated in 1:20-cv-01644.
Common defense categories in this technology area
These cases often involve:
- Non-infringement: architecture or workflow differences on hardware and software.
- Invalidity: anticipation, obviousness, lack of enablement, and indefiniteness.
- Indirect infringement: inducement and contributory theories.
- Exhaustion/conditional sale arguments for product reuse scenarios.
- Standing and license/ownership disputes.
How strong is Ravgen’s patent estate in this case?
A strength analysis needs:
- The asserted patents and their priority dates.
- Claim scope relative to prior art.
- Outcomes of validity challenges (if any).
- Whether any claims were narrowed by construction.
Without those facts, a portfolio-quality strength assessment would be incomplete.
Where is the case filed and what forum constraints apply?
Case number indicates federal district court, but a litigation-grade summary needs the court, judge assignment, and any related consolidated matters or parallel proceedings.
Forum factors that affect strategy
- S.D.N.Y. patent litigation typically produces structured claim construction schedules.
- The judge’s track record on early invalidity or claim construction can materially affect settlement posture.
Has Ravgen v. Illumina reached settlement, dismissal, or a final judgment?
A final judgment status determines:
- whether Ravgen has enforceable injunctive relief or damages awards,
- whether Illumina’s products face ongoing design-around constraints,
- whether Ravgen preserved broader leverage through remaining claims or appeal.
A definitive answer requires docket disposition.
What are the competitive and commercial implications for Illumina if infringement survives?
If claims survive construction and validity challenges, Illumina typically faces:
- Licensing exposure tied to asserted methods and workflow components.
- Design-around incentives if specific steps are found to be required.
- Potential damages exposure based on the claim-effective time window and proof of notice and willfulness (if alleged).
If claims are narrowed or invalidated, the risk shifts:
- to different claim sets within the same patent family,
- to later infringement through revised workflows or future versions,
- or to separate litigation on distinct patents.
Key Takeaways
- 1:20-cv-01644 is a Ravgen-vs-Illumina patent dispute in federal court.
- Business-critical analysis depends on the specific asserted patents, claim construction outcomes, and case disposition.
- Without the asserted patent list and docket rulings, a litigation summary cannot be completed to the standard required for licensing, investment, or litigation strategy.
FAQs
- What is Ravgen’s core infringement theory in Ravgen v. Illumina (1:20-cv-01644)?
- Which specific Illumina products are accused in the complaint for 1:20-cv-01644?
- Did the court issue claim construction (Markman) rulings in 1:20-cv-01644?
- What is the current status of 1:20-cv-01644, and has it settled?
- Do any asserted patents in 1:20-cv-01644 overlap with Illumina’s sequencing platform prior art or standard patents?
References (APA)
- PACER docket for Ravgen, Inc. v. Illumina, Inc., No. 1:20-cv-01644 (S.D.N.Y.).
- Court filings associated with Ravgen, Inc. v. Illumina, Inc., 1:20-cv-01644 (S.D.N.Y.).
